Article

Relative Effects of Tamoxifen, Raloxifene, and Conjugated Equine Estrogens on Cognition

Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
Journal of Women's Health (Impact Factor: 1.9). 02/2010; 19(3):371-9. DOI: 10.1089/jwh.2009.1605
Source: PubMed

ABSTRACT To compare the relative effects of conjugated equine estrogens (CEE), raloxifene, and tamoxifen therapies on cognition among women aged > or =65 years.
Annual Modified Mini-Mental State (3MS) examinations were used to assess global cognitive function in the two randomized placebo-controlled clinical trials of CEE therapies of the Women's Health Initiative Memory Study (WHIMS) and the Cognition in the Study of Tamoxifen and Raloxifene (CoSTAR). Analyses were limited to women who had 3MS testing at baseline and the first 3 years of follow-up and, because of potential ethnic-related differences between studies, to Caucasian women (WHIMS n = 6211, CoSTAR n = 250). Covariate adjustment was used to compare the postrandomization mean 3MS scores among the three active therapies with placebo therapy while controlling for differences between groups with respect to dementia risk factors.
At baseline, the average (SD) 3MS scores by group were 95.24 (4.28) for placebo, 95.19 (4.33) for CEE, 94.60 (4.76) for raloxifene, and 95.02 (4.03) for tamoxifen. Compared with placebo, each active therapy was associated with a small mean relative deficit in 3MS scores of < or =0.5 units, which was fairly consistent between women with and without prior hysterectomy. Relative deficits were slightly greater for tamoxifen (p = 0.001) and less marked for raloxifene (p = 0.06) and CEE (p = 0.02) therapies. Relative deficits appeared to be greater among women with lower baseline 3MS scores: p = 0.009 (tamoxifen), p = 0.08 (raloxifene), and p = 0.03 (CEE).
Although unmeasured differences between trials may have confounded analyses, these findings raise the possibility that both tamoxifen and raloxifene adversely affect cognitive function in older women; however, the magnitude of the effect is small, and the long-term consequences are unknown.

Download full-text

Full-text

Available from: Pauline M Maki, Jan 29, 2015
0 Followers
 · 
144 Views
  • Source
    Lipoprotein: The Role in Health and Diseases, 08/2012: chapter The Confounding Factor of Apolipoprotein E on Response to Chemotherapy and Hormone Regulation Altering Long-Term Cognition Outcomes: pages 255-268; Intech.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vector quantization (VQ) is a signal compression technique which can provide high compression rates, and the self-organizing map (SOM) can be employed in the generation of VQ codebooks. Exploiting the ordering property of SOM, the encoding process can be considerably accelerated by using a two-level search. In this paper, we deal with the VQ of prediction error (residual) images in image sequence coding. The results show that the codebooks generated by SOM and the widely-used LBG algorithm achieve almost the same performance, but the encoding process can be realized in a more efficient way by exploiting the ordering property of SOM
    Neural Networks, 1996., IEEE International Conference on; 07/1996
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Research increasingly suggests that changes in estrogen levels during aging may increase the risk of Alzheimer's disease, the most common type of dementia. This update reviews the newest information about estrogen and cognitive aging, including information regarding the role of bioavailable estrogen in older women and men, use of selective estrogen receptor modulators to improve cognition, and studies of genetic risk factors to elucidate the effects of endogenous estrogen on aging and cognition. Future trials are needed to determine whether alternate timing, dosage, formulation, or method of administration of hormone replacement can reduce the risk of dementia.
    Current Neurology and Neuroscience Reports 09/2010; 10(5):359-66. DOI:10.1007/s11910-010-0122-6 · 3.67 Impact Factor